Compare CCO & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | VOR |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2021 |
| Metric | CCO | VOR |
|---|---|---|
| Price | $2.40 | $18.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $2.43 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 23.24% | N/A |
| EPS Growth | ★ 110.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | N/A |
| Revenue This Year | $7.33 | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.57 | N/A |
| 52 Week Low | $1.27 | $6.50 |
| 52 Week High | $2.44 | $34.63 |
| Indicator | CCO | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 39.48 |
| Support Level | $2.37 | $13.35 |
| Resistance Level | $2.41 | $24.23 |
| Average True Range (ATR) | 0.02 | 1.28 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 81.25 | 22.54 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.